Table 1.
List of primers used and their sequence
| Genes | Primer sequence |
|---|---|
| GAPDH-F | 5′-CTGACTTCAACAGCGACACC-3′ |
| GAPDH-R | 5′-TAGCCAAATTCGTTGTCATACC-3 |
| β Actin-F | 5′-CCAGAGCAAGAGAGGCATCC-3′ |
| β Actin-R | 5′-CCGTGGTGGTGAAGCTGTAG-3′ |
| SOX2-F | 5′-CCATCCACACTCACGCAAAA-3′ |
| SOX2-R | 5′-TATACAAGGTCCATTCCCCCG-3′ |
| OCT4-F | 5′-TCCCATGCATTCAAACTGAGG-3′ |
| OCT4-R | 5′-CCAAAAACCCTGGCACAAACT-3′ |
| NANOG-F | 5′-TGGACACTGGCTGAATCCTTC-3′ |
| NANOG-R | 5′-CGTTGATTAGGCTCCAACCAT-3′ |
| BMI 1-F | 5′-AATCCCCACCTGATGTGTGT-3′ |
| BMI 1-R | 5′-GCTGGTCTCCAGGTAACGAA-3′ |
| c-MYC-F | 5′-AAACACAAACTTGAACAGCTAC-3′ |
| c-MYC-R | 5′-ATTTGAGGCAGTTTACATTATGG-3′ |
| KLF 4-F | 5′-ATCTTTCTCCACGTTCGCGTCTG-3′ |
| KLF 4-R | 5′-AAGCACTGGGGGAAGTCGCTTC-3′ |
| EZH2-F | 5′-CCCTGACCTCTGTCTTACTTGTGGA-3′ |
| EZH2-R | 5′-ACGTCAGATGGTGCCAGCAATA-3′ |
| ALDH1A1-F | 5′-CGGGAAAAGCAATCTGAAGAGG-3′ |
| ALDH1A1-R | 5′-CCCGCTCAACACTCCTTCGA-3′ |
| S100A4-F | 5′-CCACAAGTACTCGGGCAAAG-3′ |
| S100A4-R | 5′-GTCCCTGTTGCTGTCCAAGT-3′ |
| TNNT1-F | 5′-GGTCAAGGCAGAACAGAAGC-3′ |
| TNNT1-R | 5′-GCGGTTGTACAGCACGTTGA-3′ |
Table 2:
Patient details
| Hospital No | Age | Biopsy findings | Endometrial cancer type |
|---|---|---|---|
| 639043B | 56 | Endometrioid adenocarcinoma Grade I-II | Type 1 endometrial cancer |
| 707263H | 60 | High grade endometrioid adenocarcinoma (poorly differentiated) Grade III | Type 2 endometrial cancer |
Figure 1.
Represents the stemness markers and sphere-forming ability of HEC1B. (A) Flow cytometric analysis of CD133+ cells in the HEC1B cell line. (B) Spheres formation in HEC1B cells grown in serum-free media. (C) Sphere forming ability of pooled, CD133+ and CD133− cells grown in serum-free media. ****p<0.001.
Figure 2.
Represents the percentage of different fractions of cells as analysed by flow cytometry. (A) Proportion of different fractions of cells in type I endometrial cancer. (B) Proportion of different fractions of cells in type II endometrial cancer. (C) Flow cytometric analysis of the percentage of different fractions of cells in type I and type II endometrial cancer tumour samples.
Figure 3.
Expression of genes related to stemness in type 1 and type 2 endometrial cancer. Expression of genes related to stemness in type 1 and type 2 endometrial cancer.
Figure 4.
Expression genes related to maintenance of stemness and metastasis. (A) Expression of ALDH1A1 and Bmi1 in type 1 and type 2 endometrial cancer. (B) Expression of EZH2 in type 1 and type 2 endometrial cancer. (C) Expression of markers of metastasis in type 1 and type 2 endometrial cancer.